Abbott Laboratories $ABT Shares Sold by MFG Wealth Management Inc.

MFG Wealth Management Inc. lowered its holdings in Abbott Laboratories (NYSE:ABT) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,001 shares of the healthcare product maker’s stock after selling 174 shares during the quarter. Abbott Laboratories accounts for 2.1% of MFG Wealth Management Inc.’s holdings, making the stock its 26th biggest position. MFG Wealth Management Inc.’s holdings in Abbott Laboratories were worth $2,448,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Hughes Financial Services LLC purchased a new stake in Abbott Laboratories during the first quarter worth $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories during the first quarter worth $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories during the first quarter worth $30,000. Wormser Freres Gestion purchased a new stake in Abbott Laboratories during the fourth quarter worth $32,000. Finally, JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories during the first quarter worth $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ABT has been the topic of a number of recent analyst reports. Evercore ISI increased their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Morgan Stanley increased their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. BTIG Research decreased their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, July 18th. Royal Bank Of Canada increased their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Finally, William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $144.47.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $131.40 on Tuesday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The stock has a market cap of $228.70 billion, a P/E ratio of 16.47, a PEG ratio of 2.54 and a beta of 0.69. The company has a 50-day moving average price of $130.36 and a 200 day moving average price of $131.21. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the business earned $1.14 earnings per share. Abbott Laboratories’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.